BioXCell热销产品--RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)
产品描述：
10F.9G2™-CP001单克隆抗体是原始10F.9G2™单克隆抗体的重组嵌合型抗体。可变结构域序列与原始10F.9G2™克隆号相同，但是恒定区序列已经从大鼠IgG2b变为小鼠IgG1。10F.9G2™-CP001单克隆抗体在Fc片段中也含有D265A突变，使其无法与内源性Fcγ受体结合。
10F.9G2™-CP001单克隆抗体与小鼠PD-L1（程序性死亡配体1，也称为B7-H1或CD274）反应。PD-L1是属于Ig超家族的B7家族的I型跨膜蛋白，分子量为40kDa。PD-L1在T淋巴细胞、B淋巴细胞、NK细胞、树突状细胞以及IFNγ刺激的单核细胞、上皮细胞和内皮细胞上表达。PD-L1与CD4和CD8胸腺细胞以及活化的T和B淋巴细胞和骨髓细胞上的受体PD-1结合。PD-L1与PD-1的结合导致抑制TCR介导的T细胞增殖和细胞因子产生。PD-L1被认为在肿瘤免疫逃逸中起着重要作用。诱导的PD-L1表达在许多肿瘤中很常见，并导致肿瘤细胞对CD8+ T细胞介导的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通过用阻断PD-L1和PD-1之间相互作用的抗体进行治疗，暂时抑制肿瘤生长。10F.9G2™单克隆抗体已被证明可以阻断PD-L1和PD-1之间以及PD-L1和B7-1之间的相互作用（CD80）。
产品详情：
产品名称 | RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) |
产品货号 | CP001 |
产品规格 | 1mg |
反应种属 | Mouse |
克隆号 | 10F.9G2™-CP001 |
同种型 | Mouse IgG1(switched from rat IgG2b) |
免疫原 | Mouse CD274 |
实验应用 | in vivo PD-L1 blockade* Immunofluorescence* Immunohistochemistry (frozen)* Flow cytometry* Western blot* *Reported for the original rat IgG2b 10F.9G2 antibody |
产品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
纯度 | >95%, Determined by SDS-PAGE |
聚合 | <5%, Determined by SEC |
无菌处理 | 0.2 µm filtration |
纯化方式 | Protein A |
分子量 | 150 kDa |
小鼠病原检测 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
保存条件 | 抗体原液保存在4°C，不能冷冻保存。 |
推荐抗体稀释液 | InVivoPure pH 7.0 Dilution Buffer（货号IP0070） |
该产品自上市已被多篇SCI文献引用，品质有保证，以下是部分已发表的文献引用：
应用 | 文章 |
体内PD-L1阻断 (in vivo PD-L1 blockade) | 1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100.
2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247.
3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333.
4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994.
5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641. |
体内PD-L1阻断，流式细胞术 (in vivo PD-L1 blockade, Flow Cytometry) | 1. Aloulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579.
2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.
3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651. |
体内PD-L1阻断，免疫荧光 (in vivo PD-L1 blockade, Immunofluorescence) | 1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043. |
免疫组织化学（冷冻），免疫荧光 (Immunohistochemistry (frozen), Immunofluorescence) | 1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840. |
更多产品详情请咨询 BioXCell 中国授权代理——欣博盛生物
全国服务热线: 4006-800-892 邮箱: market@qckc0531.com
深圳: 0755-26755892 北京: 010-88594029
广州：020-87615159 上海: 021-34613729
代理品牌网站: www.qckc0531.com
自主品牌网站: www.neobiosescience.net